Edwards Lifesciences (WBO:EWLS) Cyclically Adjusted FCF per Share: €1.32 (As of Mar. 2026)


WBO:EWLS Edwards Lifesciences Corp WBO:EWLS
95 GF Score
Price €82.08
GF Value €80.19
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Cyclically Adjusted FCF per Share?

Edwards Lifesciences WBO:EWLS +0.02% 95 Cyclically Adjusted FCF per Share is €1.32 as of Mar. 2026. GuruFocus rates WBO:EWLS with a GF Score™ of 95/100 and a GF Value™ of €80.19 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Edwards Lifesciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.031. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.32 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Edwards Lifesciences's average Cyclically Adjusted FCF Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Edwards Lifesciences was 26.00% per year. The lowest was 3.50% per year. And the median was 17.10% per year.

As of today (2026-07-06), Edwards Lifesciences's current stock price is €82.08. Edwards Lifesciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €1.32. Edwards Lifesciences's Cyclically Adjusted Price-to-FCF of today is 62.18.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Edwards Lifesciences was 113.15. The lowest was 41.98. And the median was 71.35.


Edwards Lifesciences  (WBO:EWLS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Edwards Lifesciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=82.08/1.32
=62.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Edwards Lifesciences was 113.15. The lowest was 41.98. And the median was 71.35.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Edwards Lifesciences Cyclically Adjusted FCF per Share Related Terms


Edwards Lifesciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Cyclically Adjusted FCF per Share Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 1.30 1.33 1.32 1.32

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.21 1.26 1.32 1.32

WBO:EWLS vs BSX, GEHC, DXCM: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted Price-to-FCF falls into.


WBO:EWLS
95GF Score
Edwards Lifesciences Corp WBO:EWLS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Edwards Lifesciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.031/330.2130*330.2130
=-0.031

Current CPI (Mar. 2026) = 330.2130.

Edwards Lifesciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.153 241.018 0.210
201609 0.215 241.428 0.294
201612 0.200 241.432 0.274
201703 0.158 243.801 0.214
201706 0.187 244.955 0.252
201709 0.356 246.819 0.476
201712 0.398 246.524 0.533
201803 0.132 249.554 0.175
201806 0.117 251.989 0.153
201809 0.345 252.439 0.451
201812 0.325 251.233 0.427
201903 -0.080 254.202 -0.104
201906 0.375 256.143 0.483
201909 0.515 256.759 0.662
201912 0.468 256.974 0.601
202003 0.178 258.115 0.228
202006 0.176 257.797 0.225
202009 0.152 260.280 0.193
202012 0.367 260.474 0.465
202103 0.259 264.877 0.323
202106 0.602 271.696 0.732
202109 0.634 274.310 0.763
202112 0.392 278.802 0.464
202203 0.318 287.504 0.365
202206 0.436 296.311 0.486
202209 0.404 296.808 0.449
202212 0.297 296.797 0.330
202303 0.366 301.836 0.400
202306 -0.022 305.109 -0.024
202309 0.548 307.789 0.588
202312 0.073 306.746 0.079
202403 -0.211 312.332 -0.223
202406 0.440 314.175 0.462
202409 0.444 315.301 0.465
202412 -0.294 315.605 -0.308
202503 0.353 319.799 0.364
202506 0.355 322.561 0.363
202509 0.751 324.800 0.764
202512 0.519 324.054 0.529
202603 -0.031 330.213 -0.031

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.32 mean?
Edwards Lifesciences (WBO:EWLS) has a Cyclically Adjusted FCF per Share of €1.32 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Cyclically Adjusted FCF per Share too high?
Edwards Lifesciences' current Cyclically Adjusted FCF per Share is €1.32. Overall, Edwards Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Cyclically Adjusted FCF per Share compare to BSX and GEHC?
Edwards Lifesciences' Cyclically Adjusted FCF per Share of €1.32 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Cyclically Adjusted FCF per Share is €1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €80.19, compared to a current price of €82.08 — trading 2.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.32. Edwards Lifesciences' overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current Cyclically Adjusted FCF per Share is €1.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be overvalued. The current stock price of €82.08 is trading 2.4% above its estimated GF Value™ of €80.19. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for WBO:EWLS:

  • Cyclically Adjusted FCF per Share: €1.32
  • GF Value™: €80.19 vs. price of €82.08 (2.4% above fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
95GF Score

Get the complete analysis for WBO:EWLS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.08
Price
€80.19
GF Value